| Company name | Alexion Pharmaceuticals, Inc. |
| Stock ticker | ALXN |
| Live stock price | [stckqut]ALXN[/stckqut] |
| P/E compared to competitors | Fair |
MANAGEMENT EXECUTION
| Employee productivity | Good |
| Sales growth | Good |
| EPS growth | Poor |
| P/E growth | Good |
| EBIT growth | Poor |
ANALYSIS
| Confident Investor Rating | Fair |
| Target stock price (TWCA growth scenario) | $167.4 |
| Target stock price (averages with growth) | $160.67 |
| Target stock price (averages with no growth) | $160.67 |
| Target stock price (manual assumptions) | $156.84 |
The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/alxn
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
The Company’s product, Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Soliris is designed to inhibit a specific aspect of the component of the immune system and treat inflammation associated with chronic disorders in various therapeutic areas, including hematology, nephrology, neurology and transplant rejection. It is a humanized monoclonal antibody that blocks terminal complement activity. It is approved for the treatment of PNH in the United States, Europe, Japan and in various other territories. It is approved for the treatment of pediatric and adult patients with aHUS in the United States, Europe and Japan.
Confident Investor comments: At this time, I think that a Confident Investor can cautiously invest in Alexion Pharmaceuticals, Inc. as long as the price is correct and the indicators that I describe in my book The Confident Investor are favorable. Most of the fundamentals of this company are good but there are some concerns.
If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.
How was this analysis of Alexion Pharmaceuticals, Inc. calculated?
For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]
In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:
- Stock price at the time of the calculation: $127.15
- Growth: 0.15
- Current EPS (TTM): $1.82
- P/E: 69
- Future EPS Calc: $3.66
- Future Stock Price Calc: $252.58
- Target stock price: $156.83
[/s2If]
I hope that this makes you a Confident Investor.